Esperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Esperion Therapeutics (NASDAQ:ESPR) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04, Zacks reports.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $1.58 on Tuesday. Esperion Therapeutics has a 1 year low of $1.57 and a 1 year high of $3.94. The firm’s 50-day moving average is $2.01 and its two-hundred day moving average is $2.09. The stock has a market cap of $311.32 million, a price-to-earnings ratio of -2.47 and a beta of 1.01.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. JMP Securities reiterated a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.